The Plasma Protein Therapeutics Association (PPTA) represents the private sector manufacturers of plasma-derived and recombinant analog therapies, collectively known as plasma protein therapies and the collectors of source plasma used for fractionation. These therapies are used by patients worldwide to treat a variety of diseases and serious medical conditions. PPTA member companies produce approximately 80% of the plasma protein therapies in the U.S. and 60% of those manufactured in Europe.
PPTA works globally to:
Highlights from IPPC 2015 +
IPPC Opening Session kicked off with a panel featuring Dr. Paolo Marcucci, Dr. Giuliano Grazzini, Dr. Lorenzo Montrasio, and Patrick Robert. PPTA’s Chairman of the Global Board of Directors, Dr. Marcucci highlighted the Association’s mission “to promote the availability of and access to safe and effective plasma protein therapies for all patients in the world.”Read More
PPTA Recognizes 8th Annual International Rare Disease Day +
The Plasma Protein Therapeutics Association joins more than 300 organizations in 56 countries in recognizing the 8th annual International Rare Disease Day on February 28.
Sponsored by the National Organization of Rare Disorders and Rare Diseases Europe, Rare Diseases Day seeks to raise awareness among the general public and policymakers about rare diseases, impacting lives all over the globe.Read More
PPTA Introduces New Cross Donation Check System +
Annapolis, MD—The Plasma Protein Therapeutics Association (PPTA) recently launched the Cross Donation Check System (CDCS), a new electronic database designed to assist plasma centers in checking donors more efficiently and effectively.Read More
The Source, the international magazine of the plasma protein therapeutics industry is published quarterly. Read the current issue.